Fig. 2.

Pricing and reimbursement decisions for pertuzumab (both indications have been separated) and bosutinib in England, Germany, France and Italy. Numbers refer to the delay in decision by national bodies after EC approval (in months). Red = Not recommended; green = recommended with added value; yellow = recommended, no added value; blue = recommended, added value not quantifiable; orange = reimbursed no information on added value; white = no decision yet; mBC = metastatic breast cancer; * = no final decision has been reached by NICE; the preliminary decision from August 6, 2013 does not recommend pertuzumab; a special committee is studying this and similar cases; ^# = bosutinib was in a rapid reconsideration process at the time of article publication with decision publication expected by October 2016. Modified from [5].